AIM ImmunoTech (AIM) AI Stock Analysis

• Market Cap: $4.95M
• Dividend Yield: N/A
• Average Volume (3M): 127.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: -39.80%
• EPS Growth: 56.07%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 2,764,188
• 10 Day Avg. Volume: 67,985
• 30 Day Avg. Volume: 127,631
• PEG Ratio: 1.34
• Price to Book (P/B): -847.46
• Price to Sales (P/S): 6590.22
• P/FCF Ratio: -75.16
• Enterprise Value/Market Cap: 1.73
• Enterprise Value/Revenue: 70.56
• Enterprise Value/Gross Profit: 59.29
• Enterprise Value/Ebitda: -0.56
• 1Y Price Target: $15.00
• Price Target Upside: 474.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $1.50 ▼(-42.53% Downside)

AIM ImmunoTech's overall stock score is driven primarily by its poor financial performance and weak technical indicators. The company's negative profitability and precarious financial health are major concerns. The technical analysis indicates bearish momentum, with the stock being oversold. Valuation metrics further highlight the challenges, with a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.

Positive Factors

Product Development

Positive Phase 2 study results for Ampligen in combination with AstraZeneca's Imfinzi indicate potential for a new therapy in pancreatic cancer, enhancing long-term product development prospects.

Strategic Partnerships

Partnerships with leading institutions like AstraZeneca enhance AIM's research capabilities and credibility, potentially accelerating drug development and approval processes.

Financial Position

The $8 million raised through a public offering strengthens AIM's financial position, providing necessary capital to support ongoing R&D and operational activities.

Negative Factors

Financial Health

Negative equity and ongoing losses reflect financial instability, posing risks to AIM's ability to sustain operations and invest in growth without additional funding.

Cash Flow Issues

Persistent negative cash flows indicate challenges in generating sufficient cash to cover operational expenses, potentially hindering long-term financial sustainability.

NYSE Noncompliance

Noncompliance with NYSE equity requirements highlights governance and financial risks, potentially affecting investor confidence and access to capital markets.

AIM ImmunoTech Business Overview & Revenue Model

Company Description

AIM ImmunoTech Inc. is a biotechnology company focused on developing innovative therapies for the treatment of various immune-related diseases and conditions. The company operates primarily in the biopharmaceutical sector, specializing in drug development for cancer and viral diseases. AIM's core product, Ampligen (rintatolimod), is an experimental therapeutic intended for use in various indications, including chronic fatigue syndrome and certain cancers, aiming to enhance the immune response.

How the Company Makes Money

AIM ImmunoTech generates revenue primarily through the development and commercialization of its therapeutic products. The company seeks funding through grants, partnerships, and collaborations with other pharmaceutical firms and research institutions that are interested in its innovative drug candidates. Revenue streams may include milestone payments from partnerships, royalties from product sales, and potentially government funding for research and development projects. Additionally, AIM may explore licensing agreements for its proprietary technologies, which can further contribute to its earnings. The company's financial performance is also influenced by the progress and outcomes of its clinical trials and regulatory approvals, as successful advancements can lead to increased investment and sales opportunities.

AIM ImmunoTech Financial Statement Overview

Summary

AIM ImmunoTech faces significant financial challenges. The company is struggling with declining revenues, negative profitability, and a weak balance sheet characterized by negative equity. Cash flow issues persist, with negative operating and free cash flows. The financial health of the company is precarious, requiring strategic interventions to improve revenue generation and cost management.

Income Statement

AIM ImmunoTech's income statement reveals significant challenges. The company has experienced a decline in revenue growth, with a negative growth rate of -17.12% in the TTM. Margins are deeply negative, with a net profit margin of -104.16% and an EBIT margin of -99.80%, indicating substantial losses relative to revenue. The gross profit margin is positive at 77.40%, but the overall profitability is severely impacted by high operating expenses.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity of -$6.55 million, leading to a negative debt-to-equity ratio of -0.65. This indicates that liabilities exceed assets, posing a risk to financial stability. The return on equity is also negative at -15.86%, reflecting ongoing losses. The equity ratio is not calculable due to negative equity, further highlighting financial distress.

Cash Flow

Cash flow analysis indicates negative operating cash flow of -$10.96 million and free cash flow of -$11.52 million in the TTM. The free cash flow growth rate is negative at -11.38%, suggesting deteriorating cash generation. However, the free cash flow to net income ratio is slightly positive at 1.04, indicating that cash outflows are somewhat aligned with reported losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	121.00K	170.00K	202.00K	141.00K	135.00K	163.00K
Gross Profit	144.00K	139.00K	160.00K	-19.78M	-715.00K	-643.00K
EBITDA	-15.26M	-16.49M	-28.72M	-19.87M	-18.25M	-13.02M
Net Income	-16.17M	-17.32M	-28.96M	-21.09M	-21.51M	-16.26M
Balance Sheet
Total Assets	4.13M	8.61M	19.38M	40.49M	57.70M	64.58M
Cash, Cash Equivalents and Short-Term Investments	835.00K	3.98M	13.07M	34.19M	48.27M	39.00M
Total Debt	2.81M	2.94M	718.00K	837.00K	149.00K	2.29M
Total Liabilities	10.68M	9.93M	9.15M	2.02M	820.00K	3.29M
Stockholders Equity	-6.55M	-1.32M	10.23M	38.47M	56.88M	61.29M
Cash Flow
Free Cash Flow	-11.52M	-14.91M	-21.85M	-16.38M	-14.60M	-10.96M
Operating Cash Flow	-10.96M	-14.89M	-21.27M	-16.11M	-13.96M	-10.37M
Investing Cash Flow	5.69M	4.71M	-832.00K	10.99M	-631.00K	-9.16M
Financing Cash Flow	2.19M	6.44M	485.00K	80.00K	8.19M	56.56M

AIM ImmunoTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 2.61 is above the 20-day moving average (MA) of 2.18, above the 50-day MA of 2.45, and below the 200-day MA of 7.16, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 25.97 is Positive, neither overbought nor oversold. The STOCH value of 7.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.

AIM ImmunoTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLM	40 Underperform	$15.28M	-0.25	―	―	―	80.54%
AIM	38 Underperform	$4.95M	-0.07	―	―	-39.80%	56.07%
GTBP	34 Underperform	$6.57M	-0.15	-181.99%	―	―	46.96%
PCSA	29 Underperform	$17.42M	-0.15	-270.74%	―	―	72.88%

AIM ImmunoTech Corporate Events

AIM ImmunoTech Updates Certificate of Incorporation

AIM ImmunoTech has filed an amended and restated Certificate of Incorporation, which supersedes all previous versions. This update may have implications for the company’s governance and operational structure.

The most recent analyst rating on (AIM) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.

AIM ImmunoTech Presents at Maxim Growth Summit 2025

AIM ImmunoTech announced its participation in the Maxim Growth Summit 2025 in New York, where it will present its ongoing and future activities related to Ampligen®. The company is conducting significant testing and trials to assess Ampligen®’s effectiveness, but faces uncertainties such as regulatory approvals and trial outcomes, which could impact its operations and market positioning.

The most recent analyst rating on (AIM) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.

AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials

AIM ImmunoTech Inc. is a biotechnology company specializing in the development of immunotherapeutic treatments for cancer, viral diseases, and immune-deficiency disorders, with its main products being Ampligen and Alferon N Injection. In its latest earnings report for the quarter ending June 30, 2025, AIM ImmunoTech Inc. reported a decrease in total revenues to $25,000 from $50,000 in the same quarter last year, alongside a net loss of $2.8 million, which is an increase from the $1.8 million loss reported in the previous year. The company continues to focus on its strategic initiatives, including clinical trials for Ampligen in treating pancreatic cancer and exploring its antiviral properties. Despite the financial challenges, AIM ImmunoTech remains committed to advancing its research and development efforts, with management expressing optimism about future clinical trials and potential regulatory approvals.